Qsymia Uptake Slow, Steady, but Will It Win Obesity Race?

Four weeks after its launch, 2,000 patients were taking obesity drug Qsymia (phentermine/topiramate), from Vivus Inc., with new patient starts slowing from an initial four- or fivefold increase to a 27 percent to 33 percent increase from week three to week four, according to IMS and Wolters Kluwer weekly prescription data.